GRN expression in breast cancer patient tissue and sera is positively correlated with the more aggressive triple-negative subtype of breast cancer; associated with resistance to the breast cancer drugs tamoxifen, trastuzumab, and doxorubicin; and associated with an increased risk of tumor recurrence [33, 37-39]. Here, GRN is linked to neoplasm.